BeiGene, Ltd. (NASDAQ:BGNE) Shares Purchased by AIA Group Ltd

AIA Group Ltd raised its position in BeiGene, Ltd. (NASDAQ:BGNE) by 13.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,316 shares of the company’s stock after acquiring an additional 1,612 shares during the quarter. AIA Group Ltd’s holdings in BeiGene were worth $2,402,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. NewEdge Wealth LLC lifted its position in shares of BeiGene by 7.5% in the 4th quarter. NewEdge Wealth LLC now owns 1,612 shares of the company’s stock worth $291,000 after buying an additional 112 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of BeiGene by 350.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,856 shares of the company’s stock worth $876,000 after acquiring an additional 3,778 shares during the last quarter. JGP Global Gestao de Recursos Ltda. increased its stake in shares of BeiGene by 135.5% in the fourth quarter. JGP Global Gestao de Recursos Ltda. now owns 9,845 shares of the company’s stock valued at $1,776,000 after purchasing an additional 5,665 shares during the period. Clear Harbor Asset Management LLC bought a new stake in shares of BeiGene during the fourth quarter valued at approximately $208,000. Finally, Wellington Management Group LLP boosted its position in shares of BeiGene by 57.4% during the third quarter. Wellington Management Group LLP now owns 55,478 shares of the company’s stock worth $9,979,000 after buying an additional 20,239 shares during the period. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Insider Activity at BeiGene

In other BeiGene news, CEO John Oyler sold 26,716 shares of BeiGene stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24. Following the transaction, the chief executive officer now owns 12,084 shares in the company, valued at $1,799,186.76. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Oyler sold 26,716 shares of BeiGene stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the transaction, the chief executive officer now directly owns 12,084 shares in the company, valued at $1,799,186.76. The disclosure for this sale can be found here. Insiders sold a total of 64,781 shares of company stock valued at $10,222,381 over the last ninety days. Insiders own 7.40% of the company’s stock.

BeiGene Stock Performance

Shares of BGNE stock opened at $129.33 on Friday. The stock has a 50-day simple moving average of $155.43 and a 200 day simple moving average of $168.61. BeiGene, Ltd. has a fifty-two week low of $129.33 and a fifty-two week high of $266.67. The company has a quick ratio of 2.09, a current ratio of 2.32 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Monday, February 26th. The company reported ($3.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.08. The company had revenue of $634.40 million during the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. BeiGene’s revenue was up 66.9% on a year-over-year basis. During the same period in the prior year, the company earned ($4.29) EPS. On average, equities analysts predict that BeiGene, Ltd. will post -8.87 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on BGNE. JPMorgan Chase & Co. raised their target price on BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a research report on Tuesday, March 19th. Sanford C. Bernstein lowered their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a report on Wednesday, March 27th. Guggenheim reduced their price objective on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, Bank of America decreased their target price on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research report on Monday, April 8th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $251.70.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.